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ABSTRACT 
The aim of present work was to undertake comparative in vitro quality evaluation of six marketed clotrimazole cream formulations 
in Ethiopia with respect to physico-chemical properties like viscosity, spreadability, extrudability, pH and drug content. In vitro 
clotrimazole release from cream formulations was also studied using synthetic cellulose acetate membrane at 37 ºC in a solvent 
containing methanol and PBS 7.4 in the ratio of 75:25 as receiver medium. The cumulative amounts of the drug released over 12 h 
(µg mm-2) were analyzed. All clotrimazole cream formulations showed good and smooth homogeneous appearance with white color. 
The pH of clotrimazole cream formulations ranged from 4-7, which is a physiologically acceptable pH range and in principle devoid 
of any skin irritation. Clotrimazole content ranged from 90-110%, ensuring the uniformity of the drug content in all formulations. 
The increase in diameter of clotrimazole cream formulations following the spreadability test was found to range from 4-6 cm. Cream 
formulation D (Clotri-Denk) exhibited highest viscosity values than other formulations, whereas formulation E (Chinese 
Clotrimazole BP) showed lowest viscosity value. Cream formulation F (Mycoril) showed better extrudability and spreadability as 
compared to other formulations. Drug release from all formulations was slow in the first 6 hrs. After the 6th hr, steady drug release 
continued for formulation D and E. Fast drug release was observed in formulations A (Candid) and B (Candigen), whereas for the 
formulations C (Canesten), D and E, steady drug release pattern was observed after the 6th hr. It can be concluded that all 
clotrimazole cream formulations fulfilled the quality criteria of in-house and pharmacopeias specifications. 
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INTRODUCTION 
In vitro testing of semisolid dosage forms has become 
important tool and it has been suggested that there 
should be standard physicochemical testing parameters. 
In the manufacturing of semisolids, the in vitro release 
test can show changes in formulation composition and/or 
manufacturing processes
1
.  
Antifungal agents inhibit/impair membrane barrier 
function (Polyenes), macromolecule synthesis 
(Flucytosine), interfere with microtubules 
(Griseofulvin), or inhibit ergosterol synthesis (azole 
derivatives, morpholines). Azoles include two types: 
triazoles (Itraconazole, Voriconazole, Posaconazole) and 
the imidazoles (Clotrimazole). Azoles interfere with an 
enzyme required for the production of ergosterol, an 
important component of the fungal cytoplasmic 
membrane
2, 3
. 
Clotrimazole is a white or pale yellow, tasteless, 
crystalline powder which is practically insoluble in 
water. Clotrimazole has pH dependent solubility where 
solubility increases with decreasing pH due to presence 
of ionizable imidazole group present in its structure 
4, 5
.  
Clotrimazole was introduced as a topical agent in 1969. 
It is used for the treatment of superficial candidiasis, and 
in the skin infections: pityriasis versicolor and 
dermatophytosis. Clotrimazole may also be used 
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occasionally for symptomatic relief of the protozoal 
infection trichomoniasis when other drugs are 
contraindicated. It is also effective for prophylaxis in 
patients undergoing chemotherapy, myeloablative 
treatment, and transplant recipients and for patients with 
solid malignant neoplasms 
6, 7
. 
Clotrimazole is safer (especially in pregnant women) 
than other antifungals currently listed on the WHO 
Essential Drugs List. It is available without prescription 
in most countries and this regulatory approval status 
indicates that the drug is generally recognized as safe 
8
. 
Clotrimazole is one of the most prescribed drugs for the 
treatment of fungal infection in many health institutions 
in Ethiopia. The aim of this work was, therefore, to 
compare different brands of clotrimazole cream 
formulations available in Ethiopia. 
MATERIALS AND METHODS 
Chemicals and solvents 
The reference/working standard Clotrimazole (99.4%) 
pure was received as a gift sample from FMHACA and 
EPHARM. Potassium dihydrogen phosphate (KH2PO4) 
(Fizmerk chemicals, India) and NaOH (Scharlau Chemie 
SA, European Union) were obtained from industrial 
laboratory. Distilled water was used throughout the 
study.  
Cream formulations 
Six different Clotrimazole cream containing commercial 
formulations have been purchased from pharmacy 
outlets in Ethiopia as indicated in table 1, i.e. 
Clotrimazole BP 1% cream labelled to contain 14 gm of 
clotrimazole (SHANGHAI GENERAL PHARMA-
CEUTICALS CO.,LTD. CHINA), Canesten 1% cream 
labelled to contain 20gm of clotrimazole (Bayer PLC., 
Germany), Candid cream labeled to contain 20gm of 
clotrimazole (GLENMARK PHARMACEUTICALS 
LTD, INDIA & MAHARASHTRA), Mycoril 1% cream 
labeled to contain 20 gm  of clotrimazole (Remedica 
Ltd,Limassol industrial state, Limassol, Cyprus,EU), 
Candigen 1% cream labeled to contain 20 gm of 
clotrimazole (Galentic pharma Pvt.Ltd,India) and 
Clotri-Denk 1% cream labeled to contain 20 gm of 
clotrimazole (DENK PARMA GmbH & CO. KG, 
GERMANY). 
 
Table 1: Description of the six clotrimazole cream formulations marketed in Ethiopia 
Product Brand 
name 
%(w/w) Labeled 
Weight 
(g) 
Cost 
(Birr) 
Mfg. date Expiry 
date 
Manufacturer’s 
Name  
Country 
of origin 
A Candid  1 20 24.20 Dec, 2015 Nov, 2019 GLENMARK Pvt 
Ltd 
India 
B Candigen 1 20 18.10 Jul, 2016 Jun, 2019 Galentic Pharma 
Pvt.Ltd 
India 
C Canesten 1  20 117.05 _ 06 /2018 Bayer Plc. Germany 
D Clotri-Denk 1 20 68.00 Sept, 2016 Aug, 2019 DenkPharma 
GmbH& Co.KG 
Germany 
E Clotrimazole 
BP 
1 14 12.00 May, 2016 
 
May, 
2019 
Shangai General 
pharmaceutical 
CO.,LTD 
China 
F Mycoril 1 20 41.70 Nov, 16 Nov, 19 Remedica Ltd Cyprus-
EU 
 
Methods 
UV calibration curve  
Stock solution was prepared by dissolving 100 mg of 
clotrimazole in100 ml solvent containing methanol and 
PBS 7.4 in the ratio of 75:25. From this stock solution, 
eight different concentrations (10, 20, 30, 40, 50, 60, 70 
and 80, ug/ml) were prepared. The UV absorbance 
readings of these solutions were measured at 270 nm 
using UV/Visible spectrophotometer (CECIL, 1021, 
1000 series, England). Methanol was used as a blank. 
The values of absorbance were recorded and a standard 
curve was constructed by plotting absorbance against 
concentration. From this curve a regression line equation 
was obtained in MS Excel format. The absorbance 
versus concentration of solutions was plotted and a 
calibration curve with a linear regression equation of: 
Y= 0.0156X - 0.0345 (where, Y is the absorbance and X 
is the concentration in ug/ml) and correlation coefficient 
of 0.9991 was obtained (Figure 1). 
 
Figure 1: The UV absorption calibration curve of 
clotrimazole in methanol and PBS (pH 7.4) at 270 nm 
with 95% confidence bands for mean, (r
2
 = 0.9991). 
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Physical appearance and homogeneity 
The physical appearance and homogeneity of the 
marketed creams were tested by visual observations after 
the formulations were set in containers. All the marketed 
cream formulations were physically inspected for 
clarity/transparency, color, scent, texture, consistency, 
and homogeneity. The creams were also evaluated for 
the presence of any gritty particles 
7, 9
. 
Measurement of pH 
The pH of various formulations was determined by 
using digital pH meter (model PH-210, HANNA 
instruments, Portugal) which was calibrated prior to use 
with standard buffered solutions of pH 4, 7 and 10. The 
samples were in contact with the pH electrode until the 
reading stabilized. The electrode was thoroughly washed 
between each determination to remove all traces of the 
previous sample. The electrode was then rinsed with 
DW and dried before use.  The average of three readings 
was recorded as pH value.  
Viscosity study 
The measurement of viscosity of each cream formulation 
was determined by rotational viscometer 
(KINEMATICA, AG, Type Viscostar plus L, 
Switzerland) using different spindle numbers L3 and L4 
at shear rate of 100 rpm at room temperature. The cream 
formulations were placed in the sample holder and the 
suitable spindle selected was lowered perpendicularly 
into the sample taking care in such a way that spindle 
does not touch the bottom of the container. The spindle 
was attached to the viscometer and then it was allowed 
to rotate at a defined speed at room temperature. The 
experiment was carried out in triplicate for each sample 
10
.                                 
Spreadability of formulations 
The spreadability of each formulation was determined 
using the following technique with slight modifications: 
concentric circles of different radii were drawn on graph 
paper and a 400 cm
2
 glass plate was fixed onto it. One 
gram cream formulation was place within a circle of 2.4 
cm diameter pre-marked on a glass plate. Another 400 
cm
2
 glass plate of 123g was placed gently on the cream 
and a standardized weight of 1Kg was allowed to rest on 
the upper glass plate for 3 min. The increase in the 
diameter due to spreading of the formulation was 
recorded. The spreadability (g.cm.min
-1
) was calculated 
by using the formula:  
S = m. l/t …………………………………..   Eq. 1  
Where: S is spreadability, m is the weight of the upper 
plate and standard weight rested on it (g), l is the 
diameter of the spreading cream (cm), and t is the time 
taken (min) 
11-13
.  
Extrudability of formulations 
The method adopted for evaluating cream formulation 
for extrudability was based on the quantity in percentage 
of cream extruded from tube on application of certain 
load. The tubes were pressed to extrude the cream 
through 0.5 cm opening in 10 seconds and the 
extrudability of formulations was checked. It was then 
placed between two glass slides and was clamped. 
Extrudability was determined by weighing the amount of 
cream extruded through the tip when a constant load of 1 
Kg was placed on the slides. The percentage of cream 
extruded was calculated and grades were allotted (++++ 
excellent, i.e., for > 90% of cream extruded; +++ very 
good, i.e., for 80-89.9%; ++ good, i.e., for 70-79.9%; + 
fair, i.e., for 50-69.9% and 0 for poor, i.e., for < 50% of 
cream extruded) 
14, 15
.   
Drug content determinations 
Hundred milligrams of each formulation was taken and 
dissolved in 100ml methanol and 10ml aliquot was 
diluted in 25 ml volumetric flask. The volumetric flask 
containing the cream solution was vigorously mixed in 
order to get complete solubility of the formulation drug. 
This solution was filtered and drug content was then 
estimated spectrophotometrically at 270 nm using 
methanol as blank
16
. Clotrimazole content was computed 
as the ratio of actual amount of clotrimazole in the 
sample to theoretical amount of clotrimazole in the 
sample, expressed as a percentage 
17
. 
In vitro release study of marketed clotrimazole cream 
preparations 
In vitro release study was conducted using a glass tube 
with 100 mm height, 12.9 mm outer diameter and 12.1 
mm inner diameter (effective release area of 
approximately 115 mm
2
) filled with 1 g of the cream, 
covered with a cellulose acetate membrane (0.45 µm) 
(which was previously soaked in phosphate buffer of pH 
7.4 for about 12 hr), sealed with a rubber band (to make 
water tight), and inverted under the surface 
18, 19
 of 500 
ml of phosphate buffer of pH 7.4 at 37 ± 0.5 °C in a 
United States Pharmacopeia (USP) dissolution tester 
apparatus II, with stirring speed of 50 rpm 
10
. Samples of 
5 ml was withdrawn at 5, 15, 30, 60, 120, 180, 240, 300, 
360, 480, 600 and 720 min and replaced with an 
equivalent amount of fresh receptor medium
 20
. The 
cumulative percent drug release was determined in with 
validated UV spectrophotometer at 270 nm and the 
amount of clotrimazole released from the cream 
formulations was calculated based on the established 
standard calibration curve. Each sample was tested six 
times and mean values taken 
21-24
.   
RESULTS AND DISCUSSIONS 
Physicochemical evaluation of the cream 
formulations 
Physical appearance 
Color of all cream formulations was examined against 
black background. From the results, it is clearly evident 
that all the cream formulations showed good and smooth 
homogeneous appearance with white color. 
Measurement of pH 
The pH values of all marketed formulations ranged from 
4.0 to 7.0, among the result which are considered there is 
no significant difference of the pH value. However, for 
formulation A, the pH was altered and in neutral range 
so it is not affecting the stability of the preparations as 
well as the skin. Thus, it can be assumed that the 
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formulation is acceptable for topical applications. The 
other clotrimazole cream formulations, namely Candid 
(B), Candigen (C) and Canesten (D) and F cream 
formulations had similar pH range but Formulation E 
lowest pH value as compared the other. 
Viscosity 
Viscosity plays a vital role in the dispensing and 
formulation of topical formulations. It is related to 
mechanical and physical properties such as 
spreadability, consistency and hardness of the 
preparation which in turn are related to ease of product 
removal from container, ease of application on the target 
surface and product feel on the application site 
25
.  
As shown in Table 2, formulations B, C and D have 
nearly similar viscosity ranges and formulations A and F 
too are with similar range but with lower viscosity 
values from the previous three formulations. However 
Formulation E was the lowest viscosity value from the 
other all formulation. 
Extrudability 
The extrusion of every formulation from the tube is an 
important during its application and in patient 
acceptance. Results from extrudability indicated that 
cream formulations B, C and D had better extrudability 
than formulation A, E and F when they were extruded 
from aluminum collapsible tubes. Due to these results, 
formulations A, E and F had not extruded quickly from 
the tubes, whereas, formulations B, C and D extruded 
quickly from aluminum collapsible tube. 
Spreadability 
Spreadability is an essential attribute of topical dosage 
forms that can affect patient acceptance in terms of ease 
of application and clinical efficacy. One of the essential 
criteria for cream is that it should possess good 
spreadability. Spreadability is an important factor in 
therapy and it is shown as index of ease of application.  
The efficacy of topical therapy depends on the patient 
spreading the formulation in an even layer to deliver a 
standard dose. The optimum consistency of such a 
formulation helps ensure that a suitable dose is applied 
or delivered to the target site. This is particularly 
important with formulations of potent drugs. A reduced 
dose would not deliver the desired effect, and an 
excessive dose may lead to undesirable side effects. The 
delivery of the correct dose of the drug depends highly 
on the spreadability of the formulation
26
. The important 
factors to consider, during evaluating the spreadability 
of a formulation, include the rate and time of shear 
produced upon smearing and the temperature of the 
target site. The parallel-plate method is the most widely 
used method for determining and quantifying the 
spreadability of semisolid preparation. It provides 
accurate, reproducible, and statistically relevant data. 
The advantages of the method are simplicity and relative 
lack of expense. On the other hand, the method is not 
very precise and sensitive, and data which it generates 
must be manually interpreted and presented 
11, 26
.  
Spreadability is commonly measured by the sample 
spread diameter or area that is formed upon application 
of the weight over the sample for a predetermined time 
period. Spreading of topically applied products was 
reported to affect drug delivery as reflected by dermato-
pharmacokinetic outcome such as drug concentration in 
the stratum corneum (SC). Formulations with higher 
spreadability values allow ease of application and 
thereby increased surface area available for drug 
permeation. A good cream takes less time to spread and 
will have high spreadability 
5, 27, 28
.  
Results of spreadability as shown in Table 3.1 showed 
that cream F gave better spreadability from other 
clotrimazole cream but formulation C gave lowest 
spreadability value from the other formulation .The 
remaining formulation which is medium viscosity value 
as compare to the other above two formulations. 
Drug content 
The clotrimazole content was found to be in the range of 
90%-110% in the cream formulations. Therefore, it may 
be assumed that these formulations were applicable for 
topical application. Formulation A had highest and 
formulation E had lowest drug content value from the 
results obtained. The rank order of drug content was: 
formulation A> B> D> C> F> E. 
  
Table 2: Physico-chemical and drug content evaluation of the six clotrimazole cream formulations marketed in Ethiopia  
Brand 
name 
Labeled 
weight 
(g) 
Net weight  
(g) 
(Mean±SD) 
Physical 
appearance 
pH 
(Mean±SD) 
Viscosity 
(cP) at 100 
rpm 
(Mean±SD) 
Extrudability Spreadability 
(g.Cm/min) 
(Mean±SD)  
Drug 
Content (%) 
(Mean±SD) 
Candid 20 24.06±0.01 White 6.68±0.09 8114±23.6 + 1773±93 108.52±0.04 
Candigen 20  23.82±0.06 White 6.32±0.1 8153±11.4 +++ 2146±95 106.16±1.83 
Canesten 20 24.84±0.03 White 6.09±0.1 8152±15.3 +++ 1304±65 95.67±0.03 
Clotri-
Denk 
20 23.73±0.01 White 6.00±0.07 8157±27.73 +++ 1497±84 100.38±0.99 
Clotrimazol 14 17.24±0 White 4.45±0.21 7661±127.6 ++ 1398±98 90.82±0.05 
Mycoril 20 24.55±0.03 White 5.94±0.18 8050±31.2 ++ 3057±1543 91.47±1.72 
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In vitro release study of marketed clotrimazole 
cream preparations 
In vitro dissolution methods are developed to evaluate 
the potential in vivo performance of a semisolid dosage 
forms, and as quality control tests demonstrating the 
appropriate performance of drugs products. In recent 
years, the convergence of the increased understanding of 
the physiological environment and processes of 
absorption, critical deconstruction of the mechanisms of 
release from formulations, and improved computational 
tools has led to a more sophisticated discussion of the 
role of dissolution testing in drug product design and 
control. It is clear that meaningful results and 
interpretation of dissolution data can be achieved only 
when the biopharmaceutical and physical properties of 
the drug products are well understood, and that test 
methods are properly established through studies during 
formulation and manufacturing process design and 
clinical development
18
. 
It is expected that drug release might be influenced by 
cream viscosity. As the viscosity of the cream increased, 
the release of the drug was expected to be slower. 
Complete drug release (100%) was not achieved at the 
12
th
 hr for all marketed formulation.  Cumulative 
amount of drug released in dissolution medium showed 
extremely significant difference (P≤0.0005) which could 
be because of the differences in surfactant concentration. 
This effect may be strengthened by the ability of these 
emulsifying agents to lower the interfacial tension 
between oily and aqueous layer in the dispersion 
medium, increasing the hydrophilicity of the cream 
which in turn increases penetration of dissolution 
medium into the clotrimazole structure and then 
increasing the amount of drug released
18
. 
Drug release from all formulations was slow in the first 
6 hrs. After the 6
th
 hr, steady drug release continued for 
formulation D and E. Fast drug release was observed in 
formulations A (Candid) and B (Candigen), whereas for 
the formulations C (Canesten), D and E, steady drug 
release pattern was observed after the 6
th
 hr. 
 
 
 
Figure 2: In vitro release evaluation of six clotrimazole 
cream formulations marketed in Ethiopia 
CONCLUSIONS 
The study results indicated that marketed clotrimazole 
creams included in this study seem to have showed good 
and smooth homogeneous appearance of white color 
without any gritty particles. Cream formulation B, C and 
D showed better extrudability as compared to the other 
formulations. Cream formulation D exhibited higher 
viscosity values than other formulations, whereas 
formulation E showed lowest viscosity value. Fast drug 
release was observed in formulation A but formulation E 
showed slowest drug release. Finally, it can be 
concluded that all clotrimazole cream formulations 
fulfilled the quality criteria of in-house and 
pharmacopeias specifications.   
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